Redhill Biopharma (RDHL) Fundamental Analysis: Revenue, Earnings & Valuation

0.77 / 10

Underperform

Fundamental metrics rate Underperform with a 0.8/10 score. Strengths include a high interest coverage (27.7) and a large current‑liabilities ratio (97.8%). Weaknesses are modest revenue growth (58.6% YoY) and a high long‑term debt to working‑capital ratio (7.35), indicating defensive positioning.

Analysis Checks(5/7)

Total operating revenue (YoY growth rate %)

Value58.59

Score0/3

Weight46.89%

1M Return-4.79%

Inventory turnover ratio

Value0.47

Score2/3

Weight12.43%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value97.81

Score2/3

Weight-4.21%

1M Return0.36%

Long-term debt to working capital ratio (%)

Value7.35

Score0/3

Weight47.35%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value27.69

Score2/3

Weight12.63%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value58.59

Score3/3

Weight-27.03%

1M Return2.45%

Cost of sales ratio (%)

Value39.40

Score2/3

Weight11.94%

1M Return-1.13%

Is RDHL undervalued or overvalued?

RDHL scores 0.77/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -97.52% net margin, -0.44 P/E ratio, -0.93 P/B ratio, and 100.00% earnings growth, these metrics solidify its Underperform investment rating.